Possible interaction between lopinavir/ritonavir and valproic acid bipolar

Annals of Pharmacotherapy

Volumn 40, Issue 1, 2006, Pages 147-150

  Sheehan, Nancy L ^a,b   Brouillette, Marie Josée ^b   Delisle, Marie Soleil ^c   Allan, James ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Glucuronidation; Lopinavir; Ritonavir; Valproic acid

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450; ETHINYLESTRADIOL; ISOENZYME; LAMIVUDINE; LAMOTRIGINE; LEVOTHYROXINE; LOPINAVIR PLUS RITONAVIR; OLANZAPINE; RITONAVIR; VALPROIC ACID; ZIDOVUDINE;

ADULT; ARTICLE; BIPOLAR DISORDER; CASE REPORT; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG METABOLISM; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MANIA; MITOCHONDRIAL RESPIRATION; PATIENT MONITORING; PRIORITY JOURNAL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIPOLAR DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; PYRIMIDINONES; RITONAVIR; VALPROIC ACID;

EID: 32344438918     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G418     Document Type: Article

References (19)

1. Ketter TA, Frye MA, Corá-Locatelli G, Kimbrell TA, Post RM. Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol 1999;19:511-32.
2. Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002;43:53-9.
3. Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol 2003;65:1441-9.
4. Yu HY, Shen YZ. Glucuronidation metabolic kinetics of valproate in guinea pigs: nonlinear at clinical concentration levels. Pharm Res 1996; 13:1243-6.
5. DiCenzo R, Peterson D, Cruttenden K, et al. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2004;48:4328-31.
6. Dasgupta A, McLemore JL. Elevated free phenytoin and free valproic acid concentrations in sera of patients infected with human immunodeficiency virus. Ther Drug Monit 1998;20:63-7.
7. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999;20:147-69.
8. Kumar GN, Dykstra J, Roberts EM, et al. Potent inhibition of the cytochrome P-450 3A mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab Dispos 1999;27:902-8.
9. Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF. Interaction of anti-HIV protease inhibitors with the multidrug transporter p-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr 1998;19:203-9.
10. Package insert. Norvir (ritonavir). Saint-Laurent, Québec: Abbott Laboratories, October 2003.
11. Taburet AM, Raguin G, Le Tiec C, et al. Interaction between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2004;75:310-23.
12. Blanco-Serrano B, Otero MJ, Santos-Buelga D, García-Sánchez MJ, Serrano J, Domínguez-Gil A. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm Drug Dispos 1999;20:233-40.
13. Bertz R, Renz C, Foit C, et al. Steady-state pharmacokinetics of Kaletra (lopinavir/ritonavir 400/100 mg BID) in HIV-infected subjects when taken with food (abstract 3.10). In: Program and abstracts of the 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, Netherlands, April 2-4, 2001.
14. Quellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998;46:111-6.
15. Tseng A, Fletcher D. Interaction between ritonavir and levothyroxine. AIDS 1998;12:2235-6.
16. van der Lee MJ, Dawood L, ter Hofstede H, de Graaff M, Koopmans PP, Burger DM. The effect of lopinavir/ritonavir on the pharmacokinetics of lamotrigine in healthy individuals (abstract 12). In: Program and abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Therapy. Québec City, Canada, April 28-30, 2005.
17. Antoniou T, Gough K, Yoong D, Arbess G. Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid. Clin Infect Dis 2004;38:e38-40.
18. Tseng AL, Foisy MM. Significant interactions with new antiretrovirals and psychotropic drugs. Ann Pharmacother 1999;33:461-73. DOI 10.1345/aph.18240
19. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.